Hilliard, the HHS spokesperson, told SFGATE on Tuesday that, “Secretary [Robert F.] Kennedy [Jr.] expects the highest ethical ...

Aurinia alleges that Tidmarsh’s statements were not only inaccurate but also motivated by a personal vendetta against Kevin ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

The latest turmoil within Commissioner Marty Makary’s Food and Drug Administration, an alleged bribery scandal involving a high-level official, is no anomaly. The Sunday resignation of the Center for ...

An alleged extortion attempt, a petty yearslong grudge, shocking social media posts, and ominous text messages make up the ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.

Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...

Aurinia Pharmaceuticals ( ($AUPH) ) has issued an update. Aurinia Pharmaceuticals reported a significant increase in financial performance for the ...

Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...

An update from Aurinia Pharmaceuticals ( ($AUPH) ) is now available. Aurinia Pharmaceuticals reported significant financial growth for the third ...

On a per-share basis, the Edmonton, Alberta-based company said it had profit of 23 cents. The biotechnology company posted revenue of $73.5 million in the period, beating Street forecasts. Three ...